23:57 , Jul 13, 2017 |  BC Week In Review  |  Clinical News

Windtree's Aerosurf misses in Phase IIb for RDS

Windtree Therapeutics Inc. (OTCQB:WINT) reported top-line data from a blinded, international Phase IIb trial in 221 premature infants 28-32 weeks of gestational age with respiratory distress syndrome (RDS) showing that up to 2 repeat doses...
21:31 , Jun 16, 2017 |  BC Week In Review  |  Company News

Windtree grants Lee’s Asian rights to its KL4 surfactant products, including Aerosurf and Surfaxin

Windtree Therapeutics Inc. (OTCQB:WINT) granted Lee’s Pharmaceutical Holdings Ltd. (HKSE:950) exclusive rights to develop and commercialize KL4 surfactant products in China, Taiwan, Thailand and 13 other Asian territories based on Windtree’s KL4 surfactant and aerosolization...
19:52 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Windtree completes enrollment in Phase IIb of Aerosurf to treat RDS in premature infants

Windtree Therapeutics Inc. (OTCQB:WINT) completed enrollment of 221 premature infants 28-32 weeks of gestational age with respiratory distress syndrome (RDS) in a Phase IIb trial of Aerosurf lucinactant. The trial is comparing up to 2...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

Aerosurf lucinactant: Phase IIb started

Discovery Labs began a double-blind, international Phase IIb trial to compare up to 2 repeat doses of 25 or 50 minutes of aerosolized Aerosurf plus nasal continuous positive airway pressure (nCPAP) vs. nCPAP alone in...
07:00 , Apr 6, 2015 |  BioCentury  |  Finance

Up, up and acquired

For the first time since 1Q14, none of the biotech market cap segments fell. While the $200-$499 million tier treaded water, all other segments finished in the black, led by the $1-$4.9 billion segment. Large...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Company News

Discovery Laboratories pulmonary news

Discovery Laboratories disclosed in its 2014 financial results that it will restructure to focus on development of Aerosurf aerosolized KL4 surfactant for respiratory diseases, beginning with respiratory distress syndrome (RDS) in premature infants. Discovery Labs...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Company News

Discovery Laboratories sales and marketing update

Discovery Labs launched Surfaxin lucinactant in the U.S. to prevent respiratory distress syndrome (RDS) in premature infants. The product has a wholesale acquisition price of $860 for an 8.5 mL vial. The recommended dose is...
08:00 , Nov 4, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Amarin Corp. plc (NASDAQ:AMRN) fell $0.54 (25%) to $1.64 last week after disclosing that FDA said it no longer considers a change in serum triglyceride levels sufficient to "establish the effectiveness" of a...
01:02 , Nov 1, 2013 |  BC Extra  |  Financial News

Discovery raises $50 million in follow-on

Discovery Laboratories Inc. (NASDAQ:DSCO) raised $50 million through the sale of 25 million shares at $2 in a follow-on underwritten by Stifel; Piper Jaffray; Lazard; and Roth Capital Partners. Discovery Labs proposed the offering late...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Clinical News

Surfaxin lucinactant regulatory update

Discovery Labs confirmed that it plans to launch Surfaxin lucinactant this quarter after FDA agreed to the company's updated product specifications for the humanized lung surfactant. The agency approved Surfaxin in March 2012 to prevent...